Literature DB >> 7068961

D-Penicillamine--induced pemphigus syndrome.

C W Yung, G W Hambrick.   

Abstract

D-Penicillamine is a chelating agent which is effective in the treatment of Wilson's disease, cystinuria, and lead poisoning. In recent years, it has also been used to treat patients with rheumatoid arthritis with good results. The adverse effects of D-penicillamine are many. These include loss of taste, nephrotic syndrome, lupus erythematosus--like syndrome, polymyositis, dermatomyositis, myasthenia gravis, and agranulocytosis. Beginning in 1969, D-penicillamine was reported to induce a pemphigus eruption. We present a patient with D-penicillamine--induced pemphigus erythematosus and review previously reported cases.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7068961     DOI: 10.1016/s0190-9622(82)70022-2

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  5 in total

1.  An Update on the Treatment of the Cutaneous Manifestations of Systemic Sclerosis: The Dermatologist's Point of View.

Authors:  Magalys Vitiello; Adriana Abuchar; Néstor Santana; Luis Dehesa; Francisco A Kerdel
Journal:  J Clin Aesthet Dermatol       Date:  2012-07

2.  Bucillamine-induced pemphigus vulgaris in a patient with rheumatoid arthritis and polymyositis overlap syndrome.

Authors:  Jin-Wuk Hur; Chang-Woo Lee; Dae-Hyun Yoo
Journal:  J Korean Med Sci       Date:  2006-06       Impact factor: 2.153

3.  Pemphigus.

Authors: 
Journal:  West J Med       Date:  1983-05

4.  D-penicillamine and gold salt treatments were complicated by myasthenia and pemphigus, respectively, in the same patient with rheumatoid arthritis.

Authors:  M L Ciompi; G Marchetti; L Bazzichi; L Puccetti; M Agelli
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

5.  Pemphigus Vulgaris Associated with Rheumatoid Arthritis in a Patient not Taking Penicillamine.

Authors:  Narges Gholizadeh; Ali Taghavi Zenouz; Hossein Eslami
Journal:  J Dent Res Dent Clin Dent Prospects       Date:  2012-03-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.